Literature DB >> 10498868

Suppression of ING1 expression in sporadic breast cancer.

T Toyama1, H Iwase, P Watson, H Muzik, E Saettler, A Magliocco, L DiFrancesco, P Forsyth, I Garkavtsev, S Kobayashi, K Riabowol.   

Abstract

Down regulation of the ING1 candidate tumour suppressor promotes growth in soft agar and focus formation in vitro and tumour formation in vivo. ING1 encodes a nuclear, cell cycle-regulated protein, overexpression of which efficiently blocks cell growth and is capable of inducing apoptosis in different experimental systems. Here we present the first report of ING1 mutation and expression analysis in a total of 452 cancer samples. One germline missense alteration and three germline silent alterations were detected in 377 primary breast cancers while marked (2 - 10-fold) decreases in ING1 mRNA expression were seen in 44% of primary breast cancers and in ten of ten breast cancer cell lines examined. Furthermore, the majority of breast cancers (58%) showing decreased ING1 expression had metastasized to regional lymph nodes whereas only 9% of cancers with elevated ING1 expression, compared to adjacent normal tissues, were metastatic. Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498868     DOI: 10.1038/sj.onc.1202905

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences.

Authors:  M Scott; F M Boisvert; D Vieyra; R N Johnston; D P Bazett-Jones; K Riabowol
Journal:  Nucleic Acids Res       Date:  2001-05-15       Impact factor: 16.971

Review 2.  The ING family tumor suppressors: from structure to function.

Authors:  Almass-Houd Aguissa-Touré; Ronald P C Wong; Gang Li
Journal:  Cell Mol Life Sci       Date:  2010-08-29       Impact factor: 9.261

Review 3.  LincRNa-p21: function and mechanism in cancer.

Authors:  Shaoyun Chen; Hairong Liang; Hui Yang; Kairu Zhou; Longmei Xu; Jiaxian Liu; Bei Lai; Li Song; Hao Luo; Jianming Peng; Zhidong Liu; Yongmei Xiao; Wen Chen; Huanwen Tang
Journal:  Med Oncol       Date:  2017-04-19       Impact factor: 3.064

4.  Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma.

Authors:  Meiling Lu; Fei Chen; Qinwan Wang; Kesheng Wang; Qiuhui Pan; Xin Zhang
Journal:  Oncol Lett       Date:  2012-04-19       Impact factor: 2.967

5.  Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression.

Authors:  Wei Gong; Michael Russell; Keiko Suzuki; Karl Riabowol
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

6.  Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.

Authors:  A Nourani; Y Doyon; R T Utley; S Allard; W S Lane; J Côté
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

7.  Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast.

Authors:  G S Nouman; J J Anderson; S Crosier; J Shrimankar; J Lunec; B Angus
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 8.  The role of the tumour suppressor p33 ING1b in human neoplasia.

Authors:  G S Nouman; J J Anderson; J Lunec; B Angus
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

9.  Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia.

Authors:  G S Nouman; J J Anderson; K M Wood; J Lunec; A G Hall; M M Reid; B Angus
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

Review 10.  The ING gene family in the regulation of cell growth and tumorigenesis.

Authors:  Andrew H Coles; Stephen N Jones
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.